MacroGenics

MacroGenics Passif courant

Passif courant de MacroGenics (MGNX) au 16 nov. 2026 est 32,19 M USD. L'année précédente, Passif courant était 73,41 M USD — une variation de -56,14 % (plus faible).

Passif courant

32,19 MUSD

YoY

-56,14%

Dernière mise à jour:

Passif courant de MacroGenics est 2025 32,19 M USD. Passif courant de MacroGenics était 2024 73,41 M USD. Elle diminue ainsi de -56,14% plus faible par rapport à l'année précédente.

L'histoire de MacroGenics Passif courant

  • 3 ans

  • 10 ans

  • 25 ans

  • Max

Passif courant
Date
Passif courant
1 janv. 2018
105,26 M USD
1 janv. 2019
75,37 M USD
1 janv. 2020
88,87 M USD
1 janv. 2021
112,98 M USD
1 janv. 2022
72,32 M USD
1 janv. 2023
62,47 M USD
1 janv. 2024
73,41 M USD
1 janv. 2025
32,19 M USD
L'histoire de MacroGenics Passif courant
ANNÉEPassif courantYoY
32,19 MUSD-56,14%
73,41 MUSD+17,51%
62,47 MUSD-13,62%
72,32 MUSD-35,98%
112,98 MUSD+27,12%
88,87 MUSD+17,92%
75,37 MUSD-28,40%
105,26 MUSD+29,23%
81,45 MUSD+99,93%
40,74 MUSD+27,17%
32,04 MUSD+43,36%
22,35 MUSD+64,86%
13,55 MUSD+56,84%
8,64 MUSD-43,47%
15,29 MUSD—

Accéder à ces données via l’API Eulerpool

100 000 requêtes/mois gratuites · sans carte bancaire

MacroGenics Analyse d'actions

Que fait MacroGenics ? MacroGenics Inc is a biotechnology company that was founded in 2000 and is headquartered in Rockville, Maryland, USA. The company specializes in the research, development, and commercialization of therapeutic antibodies used in the treatment of cancer and autoimmune diseases. MacroGenics' business model is based on the production of different antibodies that primarily target various cell types and thereby selectively elicit a response. The company focuses on a balanced approach to research and development to preferentially identify cellular markers that are characteristic of certain diseases, enabling the identification of specific target molecules for antibody development. These innovative therapies lead to an improvement in the quality of life for patients by either curing severe diseases or at least keeping them in check. Over the years, MacroGenics has built several divisions, including: Antibody platform technologies MacroGenics utilizes its proprietary platform technology for phage display and antibody production (Digitalis), as well as for the discovery of target molecules responsible for specific diseases. These technologies are used for the identification of new therapeutic antibody candidates and support the entire antibody development process. Cancer research and development MacroGenics is a pioneer in the development of innovative cancer therapies. One of the key products in this area is the antibody-based cancer drug Margetuximab, which is used for the treatment of metastatic breast cancer. Another promising drug in clinical phases is MGD019, which is well suited for solid tumor treatment. Autoimmune research and development MacroGenics is a leading developer of neuromyelitis optica spectrum disorder (NMOSD), which leads to recurring inflammation of the central nervous system. Additional products in the pipeline are being developed for the treatment of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, as there is still a wide range of needs in the field of autoimmune diseases. Polyclonals and biosimilars This area encompasses the production of antibody polypeptides and biosimilar drugs. The antibody polypeptides can be used for the treatment of infectious diseases or for disease diagnosis. Biosimilar drugs are biological drugs that have similar active ingredients to other already approved drugs and are approved by the US Food and Drug Administration (FDA). These drugs are also known as generic imitation products. MacroGenics' products have proven to be safe and effective in clinical trials. The company has established an extensive network of collaborations to market and distribute its products. Partners include major pharmaceutical companies such as Pfizer, Servier, and Janssen Biotech. Overall, MacroGenics has over 20 product pipelines in various stages of development and continually works to expand its product pipelines. The company employs over 400 people and aims to revolutionize the treatment of severe and life-threatening diseases. In conclusion, MacroGenics Inc is an innovative biotechnology company that has developed and designed a variety of products to combat cancer and autoimmune diseases. The company has a wide range of proprietary platform technologies and is constantly striving to expand its product pipelines. We expect the company to continue to grow in the coming years and utilize its innovation power to further contribute to the well-being of patients. MacroGenics est l'une des entreprises les plus populaires sur Eulerpool.

Questions fréquemment posées sur l'action MacroGenics

Passif courant de MacroGenics s'élève à 32,19 M USD en 2025.

Passif courant de MacroGenics a changé de 73,41 M USD à 32,19 M USD, ce qui représente une variation de -56,14 %. La valeur est plus faible qu'l'année précédente.

Sur Eulerpool, vous trouverez l'évolution historique complète de MacroGenics de Passif courant depuis 2006 – avec des valeurs annuelles, des graphiques et une analyse détaillée.

Le passif courant comprend les obligations exigibles dans l'année, y compris les dettes fournisseurs, les dettes à court terme et les charges à payer.

USD de Passif courant est un facteur clé pour les investisseurs. Les changements dans cette métrique peuvent signaler une amélioration ou une détérioration des fondamentaux, impactant directement le cours de l'action. Sur Eulerpool, vous pouvez suivre MacroGenics de Passif courant historiquement et en temps réel.

Accéder à ces données via l’API Eulerpool

100 000 requêtes/mois gratuites · sans carte bancaire

Bilan — MacroGenics

Toutes les Métriques Clés — MacroGenics

Croissance